FATE THERAPEUTICS INC
No SEC Form 4 filings for $FATE in the last 30 days.
See all $FATE insider activity →Wedbush maintained an Outperform rating and $7 price target for Fate Therapeutics, implying a 240.6% upside from the last close. The analyst cited positive clinical results for FT819 in lupus nephritis and increased accessibility of the therapy.
Fate Therapeutics (FATE) reported Phase 1 data for FT819, its CAR T-cell therapy, showing a 50% reduction in urine protein for lupus nephritis patients. The treatment demonstrated a favorable safety profile with no serious toxicities. The company is advancing to a Phase 2 trial, RECLAIM-LN, with promising early results.
Fate Therapeutics (FATE) appointed Jamie Harrell as commercial leader. Harrell has 25 years of experience in launching autoimmune therapies, including three that topped $1B in U.S. sales. He will lead commercial strategy for FT819, in Phase 2 trials for lupus nephritis, and FT839, in Phase 1/2 trials for multiple autoimmune indications. Harrell previously worked at Aurinia Pharmaceuticals and Avalo Therapeutics.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning FATE (FATE THERAPEUTICS INC). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent FATE coverage spans technology, financial news and market movers.
Analyst upgrade and a high price target suggest fresh buying interest.
The data strengthens the risk-benefit profile for FT819 and supports momentum toward the ongoing Phase 2 RECLAIM-LN study.
The hire adds seasoned commercial expertise, potentially improving market rollout of FT819 and other CAR‑T programs.
The grant provides significant non‑dilutive capital, de‑risking the trial and may boost investor sentiment.
The grant provides non-dilutive funding for a potentially registrational trial, reducing cash burn and de‑risking the program.
AlphAI scores every news story that mentions FATE with an AI model for sentiment and relevance, and aggregates insider trades from FATE THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Wedbush maintained an Outperform rating and $7 price target for Fate Therapeutics, implying a 240.6% upside from the last close. The analyst cited positive clinical results for FT819 in lupus nephritis and increased accessibility of the therapy.
2 min readFate Therapeutics (FATE) reported Phase 1 data for FT819, its CAR T-cell therapy, showing a 50% reduction in urine protein for lupus nephritis patients. The treatment demonstrated a favorable safety profile with no serious toxicities. The company is advancing to a Phase 2 trial, RECLAIM-LN, with promising early results.
6 min readFate Therapeutics (FATE) appointed Jamie Harrell as commercial leader. Harrell has 25 years of experience in launching autoimmune therapies, including three that topped $1B in U.S. sales. He will lead commercial strategy for FT819, in Phase 2 trials for lupus nephritis, and FT839, in Phase 1/2 trials for multiple autoimmune indications. Harrell previously worked at Aurinia Pharmaceuticals and Avalo Therapeutics.
1 min readFATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Thera
2 min readFate Therapeutics (FATE) received a $15M grant from CIRM to advance FT819 in a Phase 2 trial for lupus nephritis. The RECLAIM-LN study will evaluate the off-the-shelf CAR T-cell therapy in 53 patients. Preliminary data showed favorable safety and disease activity improvements. FATE's stock closed at $2.33, up 4.72% in pre-market trading.
2 min readFate Therapeutics (FATE) will present four abstracts at ACR Convergence 2026, showcasing data on its FT819 and FT839 CAR T-cell candidates for autoimmune diseases. FT819 data includes updates on outpatient administration and quality-of-life improvements. FT839 data covers preclinical studies and Phase 1/2 trial progress. FATE stock closed at $2.35, up 0.43%, and is trading at $2.40 in premarket.
1 min readU.S. stock indices rose on Thursday, led by chipmaker stocks, with S&P 500 up 0.8%, Nasdaq 100 up 1.3%, and Dow Jones up 0.3%. Investors focused on SK Hynix's upcoming Nasdaq debut and upcoming earnings season. Oracle was downgraded by S&P Global Ratings, Starbucks is using AI to reduce reliance on legacy tech, TeraWulf plans $3.5B debt raise, Palo Alto Networks CEO commented on AI token prices, and Fate Therapeutics received FDA clearance for a clinical trial.
2 min readFate Therapeutics (NASDAQ: FATE) dosed the first patient in its Phase 2 potentially registrational RECLAIM-LN trial of FT819 for refractory moderate-to-severe SLE with Class III or IV lupus nephritis. The single-arm study targets about 53 patients, with complete renal response at Week 26 as the primary endpoint. Enrollment is expected to finish in 15-18 months, by 1H2028.
4 min readFATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated
6 min readValamehr Bahram (President and CEO) sold 43,947 shares of FATE THERAPEUTICS INC (FATE) at $2.46 ($0.11M total) on 2026-08-04.
2 min read
